Ignite Creation Date:
2025-12-24 @ 2:35 PM
Ignite Modification Date:
2026-02-08 @ 12:46 AM
Study NCT ID:
NCT05907759
Status:
RECRUITING
Last Update Posted:
2025-07-01
First Post:
2023-06-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-07-10
Start Date Type:
ACTUAL
Primary Completion Date:
2034-08-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2035-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2023-06-15
First Submit QC Date:
None
Study First Post Date:
2023-06-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-28
Last Update Post Date:
2025-07-01
Last Update Post Date Type:
ACTUAL